Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder

Main Article Content

Daniel Rivera
The University of Texas-MD Anderson Cancer Center, Department of Leukemia

Koichi Takahashi
The University of Texas-MD Anderson Cancer Center, Department of Leukemia

Jean-Benard Durand
The University of Texas-MD Anderson Cancer Center, Department of Cardiology

Alessandra Ferrajoli
The University of Texas-MD Anderson Cancer Center, Department of Leukemia

Keywords

Ibrutinib-related side effects, Chronic Lymphocytic Leukemia

Abstract

Ibrutinib is a well-tolerated and effective therapy used for the treatment of chronic lymphocytic leukemia (CLL). Its use has been associated with cardiovascular events such as atrial fibrillation (Afib), hypertension, and ventricular arrhythmias. Implanted loop recorders are a useful tool in guiding the management of patients with cardiac arrhythmias.

Downloads

Download data is not yet available.


Abstract 680
PDF Downloads 220
HTML Downloads 74

References

1. Burger, J.A., et al., Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia, 2020. 34(3): p. 787-798.
2. Munir, T., et al., Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol, 2019. 94(12): p. 1353-1363.
3. McMullen, J.R., et al., Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood, 2014. 124(25): p. 3829-30.
4. Xiao, L., et al., Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation, 2020. 142(25): p. 2443-2455.
5. Dickerson, T., et al., Hypertension and incident cardiovascular events following ibrutinib initiation. Blood, 2019. 134(22): p. 1919-1928.
6. Leong, D.P., et al., The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood, 2016. 128(1): p. 138-40.
7. Thompson, P.A., et al., Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood, 2016. 127(3): p. 303-9.
8. Guha, A., et al., Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies. J Am Coll Cardiol, 2018. 72(6): p. 697-698.
9. Maddocks, K.J., et al., Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol, 2015. 1(1): p. 80-7.

Article Sidebar

PDF HTML
Published
Jun 28, 2021
DOI https://doi.org/10.4084/MJHID.2021.044

Article Details

How to Cite

Rivera, D. (2021) “Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder”, Mediterranean Journal of Hematology and Infectious Diseases, 13(1), p. e2021044. doi: 10.4084/MJHID.2021.044.
Issue
Vol. 13 No. 1 (2021): Mediterranean Journal of Hematology and Infectious Diseases, Volume 13, 2021
Section
Case Reports
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.